Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIAN
2024-516779-33-00Phase 2Authorised
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib and dostarlimab in head and neck squamous cell carcinoma (HNSCC), oropharyngeal squamous cell carcinoma (OPSCC), laryngeal squamous cell carcinoma (LSCC) and 2 more (2 cohorts), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: 1-year disease-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
niraparibdostarlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)oropharyngeal squamous cell carcinoma (OPSCC)laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynxOral Mucosal Carcinoma
Beyond the preview
Go deeper on 2024-516779-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516779-33-00.